5.440USDMkt Cap: 891.30M USDP/E: —Last update: 2026-05-21
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibod…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap891.30M USD
Enterprise Value691.71M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-206.69M USD
Revenue/Share—
Last Price5.440 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees93
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.89
PEG—
EV/EBITDA-3.41
EV/Revenue—
P/S—
P/B4.32
EPS (TTM)-1.20
EPS (Forward)-0.92
52W Range
4.88097% of range5.455
52W High5.455 USD
52W Low4.880 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.66%
ROA-74.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-186.36M USD
CapEx (TTM)137.00K USD
FCF Margin—
FCF Yield-12.04%
Net Debt-199.59M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.12
Current Ratio6.35
Quick Ratio6.26
Book Value/Sh1.259 USD
Cash/Share1.373 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)13.13 USD
Target Range7.000 USD – 27.00 USD
# Analysts8
Ownership
Shares Out.163.84M
Float130.01M
Insiders0.47%
Institutions102.64%
Short Interest
Short Ratio9.6d
Short % Float15.42%
Short % Out.14.43%
Shares Short23.44M
Short (prev mo.)18.64M
Technical
SMA 505.654 (-3.8%)
SMA 2004.455 (+22.1%)
Beta1.22
S&P 52W Chg28.31%
Avg Vol (30d)2.89M
Avg Vol (10d)2.18M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—